 Mayumi Nakagawa
Concepts (217)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 15 | 2024 | 168 | 4.570 |
Why?
| | Human papillomavirus 16 | 11 | 2021 | 44 | 3.610 |
Why?
| | Uterine Cervical Neoplasms | 10 | 2024 | 276 | 3.380 |
Why?
| | Papillomavirus Vaccines | 7 | 2021 | 67 | 3.290 |
Why?
| | Oncogene Proteins, Viral | 11 | 2011 | 52 | 2.460 |
Why?
| | Papillomaviridae | 7 | 2019 | 103 | 2.320 |
Why?
| | Repressor Proteins | 9 | 2011 | 148 | 2.100 |
Why?
| | Epitopes, T-Lymphocyte | 7 | 2018 | 25 | 1.910 |
Why?
| | Cancer Vaccines | 3 | 2021 | 80 | 1.610 |
Why?
| | T-Lymphocytes | 6 | 2021 | 325 | 1.430 |
Why?
| | Candida | 4 | 2018 | 59 | 1.340 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2018 | 125 | 1.310 |
Why?
| | Cervix Uteri | 3 | 2021 | 42 | 0.880 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2015 | 49 | 0.840 |
Why?
| | Immunity, Cellular | 4 | 2013 | 63 | 0.730 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 76 | 0.720 |
Why?
| | Epitopes | 2 | 2015 | 59 | 0.710 |
Why?
| | Langerhans Cells | 3 | 2018 | 11 | 0.700 |
Why?
| | Neoplasms | 2 | 2021 | 1254 | 0.670 |
Why?
| | Viral Load | 2 | 2019 | 76 | 0.660 |
Why?
| | Health Education | 1 | 2021 | 153 | 0.650 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 29 | 0.640 |
Why?
| | HLA Antigens | 4 | 2006 | 52 | 0.620 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 260 | 0.580 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2018 | 158 | 0.570 |
Why?
| | Humans | 40 | 2024 | 50509 | 0.570 |
Why?
| | Adult | 20 | 2021 | 13583 | 0.560 |
Why?
| | Female | 28 | 2024 | 27086 | 0.550 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 491 | 0.530 |
Why?
| | Plasma Exchange | 2 | 2014 | 25 | 0.510 |
Why?
| | Cross Protection | 1 | 2015 | 5 | 0.490 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2016 | 82 | 0.490 |
Why?
| | Colposcopy | 1 | 2015 | 17 | 0.480 |
Why?
| | Interleukin-12 | 2 | 2018 | 29 | 0.470 |
Why?
| | Adjuvants, Immunologic | 2 | 2018 | 51 | 0.470 |
Why?
| | Immunity, Innate | 1 | 2015 | 105 | 0.450 |
Why?
| | Interferon-gamma | 2 | 2012 | 177 | 0.440 |
Why?
| | Health | 1 | 2013 | 23 | 0.440 |
Why?
| | Lectins, C-Type | 1 | 2013 | 30 | 0.440 |
Why?
| | Papillomavirus E7 Proteins | 8 | 2018 | 31 | 0.440 |
Why?
| | Young Adult | 9 | 2021 | 4106 | 0.430 |
Why?
| | Patient Selection | 1 | 2015 | 259 | 0.420 |
Why?
| | Middle Aged | 14 | 2021 | 12614 | 0.410 |
Why?
| | Afibrinogenemia | 1 | 2012 | 5 | 0.400 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2012 | 3 | 0.400 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2009 | 63 | 0.390 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1201 | 0.390 |
Why?
| | Cell Proliferation | 5 | 2021 | 985 | 0.370 |
Why?
| | Vaginal Smears | 3 | 2021 | 28 | 0.370 |
Why?
| | Early Detection of Cancer | 3 | 2021 | 163 | 0.360 |
Why?
| | Warts | 1 | 2010 | 13 | 0.360 |
Why?
| | Plateletpheresis | 1 | 2010 | 7 | 0.360 |
Why?
| | Antigens, Fungal | 1 | 2010 | 19 | 0.360 |
Why?
| | Blood Preservation | 1 | 2010 | 26 | 0.350 |
Why?
| | Dermatitis | 1 | 2010 | 35 | 0.350 |
Why?
| | Blood Proteins | 1 | 2010 | 84 | 0.340 |
Why?
| | Anaphylaxis | 1 | 2010 | 69 | 0.340 |
Why?
| | Cells, Cultured | 5 | 2021 | 1571 | 0.320 |
Why?
| | Antigens, Viral | 2 | 2009 | 42 | 0.310 |
Why?
| | Immunotherapy | 1 | 2010 | 235 | 0.310 |
Why?
| | Telemedicine | 1 | 2015 | 469 | 0.300 |
Why?
| | Human papillomavirus 18 | 1 | 2008 | 9 | 0.300 |
Why?
| | Blood Platelets | 1 | 2010 | 251 | 0.290 |
Why?
| | Host-Pathogen Interactions | 2 | 2021 | 135 | 0.290 |
Why?
| | Dendritic Cells | 1 | 2008 | 135 | 0.280 |
Why?
| | Vaccinia virus | 1 | 2007 | 6 | 0.280 |
Why?
| | Immunoenzyme Techniques | 1 | 2007 | 137 | 0.270 |
Why?
| | Immunophenotyping | 1 | 2007 | 105 | 0.270 |
Why?
| | Cell Line, Tumor | 5 | 2021 | 1398 | 0.240 |
Why?
| | Isoantibodies | 1 | 2004 | 29 | 0.230 |
Why?
| | Neoplasm Grading | 2 | 2021 | 122 | 0.230 |
Why?
| | Lead | 1 | 2004 | 34 | 0.230 |
Why?
| | Aged | 9 | 2021 | 9743 | 0.230 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2004 | 48 | 0.230 |
Why?
| | Neutropenia | 1 | 2004 | 116 | 0.220 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.220 |
Why?
| | DNA, Viral | 3 | 2011 | 136 | 0.220 |
Why?
| | Anus Neoplasms | 1 | 2024 | 24 | 0.220 |
Why?
| | Coinfection | 1 | 2024 | 41 | 0.210 |
Why?
| | Blood Transfusion | 1 | 2004 | 129 | 0.210 |
Why?
| | Penile Neoplasms | 1 | 2024 | 44 | 0.210 |
Why?
| | Adolescent | 5 | 2021 | 6447 | 0.210 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2021 | 170 | 0.210 |
Why?
| | Antibody Formation | 1 | 2002 | 50 | 0.200 |
Why?
| | Capsid Proteins | 1 | 2002 | 24 | 0.200 |
Why?
| | Clone Cells | 3 | 2007 | 70 | 0.190 |
Why?
| | Genes, T-Cell Receptor | 1 | 2021 | 5 | 0.190 |
Why?
| | Treatment Outcome | 3 | 2021 | 5285 | 0.190 |
Why?
| | Cytokines | 2 | 2016 | 606 | 0.190 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 25 | 0.190 |
Why?
| | Pilot Projects | 2 | 2021 | 699 | 0.190 |
Why?
| | Mass Screening | 2 | 2021 | 344 | 0.180 |
Why?
| | Remission Induction | 1 | 2021 | 208 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2021 | 71 | 0.180 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 164 | 0.180 |
Why?
| | Videotape Recording | 1 | 2021 | 26 | 0.180 |
Why?
| | Left-Right Determination Factors | 1 | 2020 | 1 | 0.180 |
Why?
| | Nodal Protein | 1 | 2020 | 3 | 0.180 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 574 | 0.180 |
Why?
| | Mammography | 1 | 2021 | 101 | 0.180 |
Why?
| | Focus Groups | 1 | 2021 | 194 | 0.170 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 234 | 0.170 |
Why?
| | Male | 10 | 2024 | 25910 | 0.160 |
Why?
| | Metagenome | 1 | 2019 | 40 | 0.160 |
Why?
| | Glioblastoma | 1 | 2020 | 94 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1372 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2021 | 391 | 0.160 |
Why?
| | Parenteral Nutrition | 1 | 2019 | 28 | 0.160 |
Why?
| | Up-Regulation | 1 | 2020 | 446 | 0.160 |
Why?
| | Health Behavior | 1 | 2021 | 253 | 0.150 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 87 | 0.150 |
Why?
| | DNA | 1 | 2021 | 535 | 0.150 |
Why?
| | Time Factors | 2 | 2021 | 2934 | 0.150 |
Why?
| | Bacteria | 1 | 2019 | 218 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 2 | 2016 | 118 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2012 | 2997 | 0.140 |
Why?
| | HLA-B Antigens | 2 | 2008 | 7 | 0.140 |
Why?
| | Cell Line | 2 | 2012 | 988 | 0.140 |
Why?
| | Age Factors | 1 | 2021 | 1110 | 0.140 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 450 | 0.140 |
Why?
| | Brain Neoplasms | 1 | 2020 | 291 | 0.140 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2008 | 37 | 0.130 |
Why?
| | Vaccines, Subunit | 1 | 2016 | 15 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 288 | 0.130 |
Why?
| | Body Mass Index | 1 | 2019 | 677 | 0.120 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 778 | 0.120 |
Why?
| | Adaptive Immunity | 1 | 2015 | 32 | 0.120 |
Why?
| | Chromatography, Liquid | 1 | 2016 | 231 | 0.120 |
Why?
| | Leukocyte Count | 2 | 2004 | 69 | 0.120 |
Why?
| | Peptides | 2 | 2006 | 221 | 0.120 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 238 | 0.120 |
Why?
| | Factor VIII | 1 | 2014 | 23 | 0.120 |
Why?
| | ADAM Proteins | 1 | 2014 | 20 | 0.110 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 16 | 0.110 |
Why?
| | Proteome | 1 | 2016 | 169 | 0.110 |
Why?
| | Mannose-Binding Lectins | 1 | 2013 | 7 | 0.110 |
Why?
| | Antigens, CD1 | 1 | 2013 | 8 | 0.110 |
Why?
| | Receptors, Pattern Recognition | 1 | 2013 | 4 | 0.110 |
Why?
| | Indicators and Reagents | 1 | 2013 | 37 | 0.110 |
Why?
| | Intracellular Space | 1 | 2013 | 25 | 0.110 |
Why?
| | Skin Tests | 1 | 2013 | 55 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 578 | 0.110 |
Why?
| | Vaccination | 1 | 2016 | 280 | 0.110 |
Why?
| | Cadherins | 1 | 2013 | 63 | 0.110 |
Why?
| | Proteomics | 1 | 2016 | 314 | 0.110 |
Why?
| | Communication | 1 | 2015 | 250 | 0.100 |
Why?
| | Research Design | 1 | 2015 | 352 | 0.100 |
Why?
| | Rural Health Services | 1 | 2015 | 169 | 0.100 |
Why?
| | Antigens, CD | 1 | 2013 | 222 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 572 | 0.100 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 591 | 0.100 |
Why?
| | Longitudinal Studies | 2 | 2005 | 734 | 0.090 |
Why?
| | Injections, Intralesional | 1 | 2010 | 31 | 0.090 |
Why?
| | Isotonic Solutions | 1 | 2010 | 17 | 0.090 |
Why?
| | Platelet Transfusion | 1 | 2010 | 29 | 0.090 |
Why?
| | P-Selectin | 1 | 2010 | 32 | 0.090 |
Why?
| | Sodium Chloride | 1 | 2010 | 55 | 0.090 |
Why?
| | Platelet Aggregation | 1 | 2010 | 70 | 0.090 |
Why?
| | Platelet Activation | 1 | 2010 | 45 | 0.090 |
Why?
| | Hypersensitivity | 1 | 2010 | 75 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2019 | 6263 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 449 | 0.080 |
Why?
| | HLA-A Antigens | 1 | 2008 | 10 | 0.080 |
Why?
| | Antigen Presentation | 1 | 2008 | 25 | 0.080 |
Why?
| | Immunologic Memory | 1 | 2008 | 29 | 0.070 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2008 | 46 | 0.070 |
Why?
| | Signal Transduction | 2 | 2020 | 1624 | 0.070 |
Why?
| | DNA, Recombinant | 1 | 2007 | 15 | 0.070 |
Why?
| | Animals | 2 | 2019 | 13124 | 0.070 |
Why?
| | Genes, MHC Class I | 1 | 2006 | 10 | 0.070 |
Why?
| | Arkansas | 1 | 2013 | 1984 | 0.070 |
Why?
| | Binding, Competitive | 1 | 2006 | 94 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2008 | 746 | 0.060 |
Why?
| | Calgranulin B | 1 | 2005 | 4 | 0.060 |
Why?
| | Calgranulin A | 1 | 2005 | 5 | 0.060 |
Why?
| | Immunomagnetic Separation | 1 | 2004 | 7 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2004 | 6 | 0.060 |
Why?
| | Risk Factors | 1 | 2013 | 3724 | 0.060 |
Why?
| | Phosphorylation | 2 | 2020 | 525 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 861 | 0.050 |
Why?
| | Tumor Virus Infections | 1 | 2002 | 47 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2002 | 94 | 0.050 |
Why?
| | Lactobacillus | 1 | 2021 | 6 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2002 | 187 | 0.050 |
Why?
| | SOX Transcription Factors | 1 | 2021 | 4 | 0.050 |
Why?
| | Neuroendocrine Cells | 1 | 2021 | 10 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2021 | 21 | 0.050 |
Why?
| | Cytodiagnosis | 1 | 2021 | 41 | 0.050 |
Why?
| | Cytoplasm | 1 | 2021 | 89 | 0.050 |
Why?
| | Cobalt | 1 | 2020 | 16 | 0.040 |
Why?
| | Recurrence | 1 | 2002 | 659 | 0.040 |
Why?
| | Cohort Studies | 1 | 2004 | 1452 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2020 | 47 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2020 | 82 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2021 | 98 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 51 | 0.040 |
Why?
| | Cell Movement | 1 | 2021 | 247 | 0.040 |
Why?
| | Community Health Workers | 1 | 2020 | 51 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 583 | 0.040 |
Why?
| | Parenteral Nutrition, Total | 1 | 2019 | 31 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 226 | 0.040 |
Why?
| | Cell Survival | 1 | 2020 | 589 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2021 | 640 | 0.040 |
Why?
| | Phenotype | 1 | 2021 | 739 | 0.040 |
Why?
| | Linear Models | 1 | 2019 | 279 | 0.040 |
Why?
| | Models, Biological | 1 | 2021 | 716 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2018 | 22 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2004 | 2747 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 833 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 1978 | 0.030 |
Why?
| | Autoantibodies | 1 | 2014 | 115 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 225 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 1808 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 641 | 0.020 |
Why?
| | Mice | 1 | 2018 | 5687 | 0.020 |
Why?
| | Casein Kinase II | 1 | 2005 | 10 | 0.010 |
Why?
| | Cell Division | 1 | 2005 | 291 | 0.010 |
Why?
|
|
Nakagawa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|